Royalty Pharma plc P/Gross Profit LTM
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|
| P/Gross Profit LTM | 19.4x | 8.0x | 11.2x | 7.5x | 7.1x |
Royalty Pharma plc (RPRX) P/Gross Profit LTM comparison analysis
General
LTM P/Gross Profit LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
RPRX key stats
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,652.4 0.0% | 1,877.4 13.6% | 1,597.9 (14.9%) | 1,794.9 12.3% | 1,814.3 1.1% | 2,122.0 17.0% | 2,289.5 7.9% | 2,237.2 (2.3%) | 2,354.6 5.2% | 2,264.0 (3.8%) |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 33.3 | 136.0 | 1,019.3 | 88.1 | 23.0 | 5.7 | 560.7 | 0.0 |
% margin | 1,652.4 100.0% | 1,877.4 100.0% | 1,564.7 97.9% | 1,658.9 92.4% | 794.9 43.8% | 2,033.9 95.8% | 2,266.5 99.0% | 2,231.5 99.7% | 1,793.9 76.2% | 2,264.0 100.0% |
| Operating Expenses | 790.0 | 1,086.3 | 658.2 | 430.4 | (808.9) | 527.0 | 858.7 | 1,314.3 | 862.4 | 971.0 |
| Research & Development Expenses (R&D) | 98.4 | 91.0 | 117.9 | 392.6 | 83.0 | 26.0 | 200.1 | 177.1 | 52.0 | 2.0 |
| Selling, General & Administrative Expenses (SG&A) | 121.4 | 69.5 | 106.4 | 61.9 | 103.4 | 182.0 | 182.8 | 227.3 | 249.7 | 237.0 |
% margin | 794.3 48.1% | 722.9 38.5% | 939.7 58.8% | 1,364.4 76.0% | 2,623.2 144.6% | 1,595.0 75.2% | 1,430.7 62.5% | 977.5 43.7% | 1,492.2 63.4% | 1,292.0 57.1% |
| Interest Income | 0.0 | 0.0 | 6.8 | 24.4 | 22.3 | 28.4 | 53.5 | 78.3 | 72.3 | 0.0 |
| Interest Expense | 224.4 | 238.9 | 247.3 | 280.0 | 268.6 | 157.0 | 166.1 | 188.0 | 187.2 | 226.0 |
| Pre-tax Income | 758.7 | 761.9 | 1,343.2 | 1,517.9 | 2,461.4 | 1,702.0 | 1,241.2 | 230.1 | 1,700.1 | 1,331.0 |
% effective tax rate | 177.3 23.4% | 196.0 25.7% | 542.7 40.4% | 433.4 28.6% | 349.3 14.2% | 1,147.0 67.4% | 762.4 61.4% | 187.2 81.4% | 0.0 0.0% | 472.0 35.5% |
% margin | 581.4 35.2% | 565.9 30.1% | 1,210.0 75.7% | 1,377.7 76.8% | 2,348.5 129.4% | 495.2 23.3% | 478.8 20.9% | 42.8 1.9% | 1,134.8 48.2% | 859.0 37.9% |
| EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 3.41 | 1.92 |
| Diluted EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 2.53 | 1.45 |
% margin | 862.4 52.2% | 1,069.0 56.9% | 973.0 60.9% | 1,397.7 77.9% | 2,647.1 145.9% | 1,683.5 79.3% | 1,453.7 63.5% | 928.6 41.5% | 1,887.3 80.2% | 1,292.0 57.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Royalty Pharma plc's P/Gross Profit LTM?
As of today, Microsoft Corp's last 12-month P/Gross Profit LTM is 7.1x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/Gross Profit LTM for Royalty Pharma plc have been 9.3x over the past three years, and 10.7x over the past five years.
2) Is Royalty Pharma plc's P/Gross Profit LTM Good?
As of today, Royalty Pharma plc's P/Gross Profit LTM is 7.1x, which is higher than industry median of 5.0x. It indicates that Royalty Pharma plc's P/Gross Profit LTM is Bad.